IMPROVE NEURAL FUNCTIONING & COGNITIVE SYMPTOMS
Akili's flagship product line from the Project: EVO™ platform provides a targeted way to potentially improve cognition and disease symptoms through entirely at-home digital interactions. These treatment products provide Akili’s proprietary interference™ processing therapy with the aim of improving symptoms of inattention, working memory, and executive function. High-res data collection enables patient compliance tracking and progress analytics for multiple stakeholders. The leading product, Project: EVO™ ADHD, is currently being evaluated in the STARS-ADHD study. Akili plans to seek approval from the United States Food and Drug administration for this potential first-in-class treatment if the results of the pivotal study are favorable. Additional customized treatment products from this platform are being tested in Autism, depression, Alzheimer’s disease, and traumatic brain injury.
FREQUENT AND SENSITIVE COGNITION measurement
We believe that traditional cognitive tests are barely tolerable by the patient and can lack the sensitivity needed for subtle patient characterization and multiple time point engagement. Measurements over time allow for a plethora of uses, from tracking patients' conditions to understanding the effect of interventions on brain function. Monitor product allows for short measurements configurable to custom tracking needs (hourly, daily, weekly, etc.). Each individual assessment utilizes the Project: EVO™ platform’s proprietary measurement of cognitive control in a format that engages the patient. Our goal is higher quality, ultra-frequent, more sensitive cognitive data for use in clinical decision making and clinical trials.
If you want to give your patients a brand new medical experience by running an innovative clinical trial with our software platform, Get in Touch!